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Abstract
Background: Parkinson’s disease is characterized by a progressive loss of dopaminergic neurons in the substantia
nigra. The cause of the neurodegeneration is unknown. Neuroinflammation has been clearly shown in Parkinson’s
disease and may be involved in the progressive nature of the disease. Microglia are capable of producing neuronal
damage through the production of bioactive molecules such as cytokines, as well as reactive oxygen species (ROS),
and nitric oxide (NO). The inflammatory response in the brain is tightly regulated at multiple levels. One form of
immune regulation occurs via neurons. Fractalkine (CX3CL1), produced by neurons, suppresses the activation of
microglia. CX3CL1 is constitutively expressed. It is not known if addition of exogenous CX3CL1 beyond otherwise
physiologically normal levels could decrease microglia activation and thereby minimize the secondary
neurodegeration following a neurotoxic insult.
Methods: The intrastriatal 6-hydroxydopamine (6-OHDA) rat model of Parkinson disease, was used to test the
hypothesis that exogenous CX3CL1 could be neuroprotective. Treatment with recombinant CX3CL1 was delivered
to the striatum by an osmotic minipump for 28 days beginning 7 days after the initial insult. Unbiased
stereological methods were used to quantify the lesion size in the striatum, the amount of neuronal loss in the
substantia nigra, and the amount of microglia activation.
Results: As hypothesized, CX3CL1 was able to suppress this microglia activation. The reduced microglia activation
was found to be neuroprotective as the CX3CL1 treated rats had a smaller lesion volume in the striatum and
importantly significantly fewer neurons were lost in the CX3CL1 treated rats.
Conclusion: These findings demonstrated that CX3CL1 plays a neuroprotective role in 6-OHDA-induced
dopaminergic lesion and it might be an effective therapeutic target for many neurodegenerative diseases,
including Parkinson disease and Alzheimer disease, where inflammation plays an important role.
Background
Parkinson’s disease (PD) is a neurodegenerative disorder
affecting the motor system including motor coordina-
tion and speed as well as producing rigidity and tremor.
The symptoms of PD are mainly due to a progressive
loss of dopaminergic neurons within the pars compacta
of the substantia nigra (SNpc). This degeneration
decreases the levels of the neurotransmitter dopamine
in the nigrostriatal system. In the past 15 years, an
increasing amount of evidence has emerged to suggest
that inflammation may contribute to nigrostriatal
pathway degeneration and accelerate the progression of
pathology in PD patients. Within the microenvironment
of the brain, glial cells play a critical role in homeostatic
mechanisms that promote neuronal survival. There is a
long history demonstrating, at least a casual link, in
humans between microglia activation and PD, including
early studies, which showed activated microglia in the
substantia nigra of PD patients and people exposed to
MPTP [1,2]. The contribution of microglia activation to
the degenerative process in PD is presently unknown,
but is likely to have a damaging rather than a beneficial
role [3].
In animal models that mimic many aspects of
Parkinson disease, activated microglia have been
shown capable of damaging and killing neurons (For
reviews on the topic see: [3,4]). However microglia do
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any medium, provided the original work is properly cited.not typically kill neurons unless they are activated by a
‘danger signal’ such as the release of ATP, DNA, or
mitochondria from a cell, which can occur when a cell
dies and is not efficiently cleared [5]. While ‘danger
signals’ can activate microglia there are also a number
of suppressive signals that neurons use to induce
‘immune tolerance’ t op r o t e c tt h en e u r o n sf r o mb e i n g
killed. Recent evidence indicates that neurons are not
only passive targets of microglia but rather can control
microglial activity. Fractalkine (CX3CL1) is one of the
signals that neurons constitutively express that plays a
‘calming’ role to reduce microglial activation by liga-
tion of CX3CL1 to a G-protein coupled receptor
(CX3CR1) present on microglia. CX3CL1 is a trans-
membrane chemokine and exists in both membrane-
bound and soluble forms. Its membrane-bound form
displays adhesion properties and consists of an intra-
cellular domain and a transmembrane domain [6,7].
Soluble CX3CL1 form results from the cleavage of
membrane-bound CX3CL1 by the metalloproteinase
ADAM 10 and ADAM 17 [8,9].
In contrast to many other chemokines, CX3CL1 binds
to only one receptor (CX3CR1). This receptor responds
to membrane-bound CX3CL1 and to the soluble form.
CX3CL1 acts in vitro as an anti-inflammatory molecule
by down regulating IL-1b,T N F - a and, IL-6 production
[10,11]. CX3CL1 has an essential role in protecting the
brain from a dysregulated microglial response that leads
to neurotoxicity [12]. Yet, while it is clear that complete
loss of CX3CL1 signaling leaves neurons susceptible to
microglia mediated neuronal injury and death, however
it is not clear if supraphysiological levels of CX3CL1
would be neuroprotective. CX3CL1 and the CX3CL1
receptor are normally expressed at relatively high levels
in the brain [12,13]. It has been shown that there are
age related changes in CX3CL1 [14,15], but there is not
a complete loss. Moreover, it is not known, at normal
physiological conditions, if CX3CL1 or the CX3CR1 are
in excess. As this signaling pathway is very important
for regulating inflammation in the brain, it is likely that
the ligand would be in excess to ensure tight regulation
of the immune response. When neurons are lost there
will be changes to the levels of CX3CL1. Surrounding
‘healthy’ neurons could be left vulnerable to the neu-
roinflammatory response due to the altered local
CX3CL1 changes. Therefore, this study sought to deter-
mine if the CX3CL1 pathway could be a therapeutic tar-
get to prevent excessive microglia activation that
contributes to neurodegenerative disease in the 6-
OHDA, toxin induced, model of Parkinson’sd i s e a s e .
The results of this study demonstrate that even small
increases in CX3CL1 can be neuroprotective, by sup-
pressing microglia activation.
Methods
Animals
All experiments were conducted in accordance with the
National Institute of Health Guide and Use of Labora-
tory Animals, and were approved by the Institutional
Animal Care and Use committee of the University of
South Florida, College of Medicine. 3 months old male
Fisher 344 (F344) rats (Harlan Sprague Dawley, Indiana-
polis, IN), were pair-housed in environmentally con-
trolled conditions (12:12 h light:dark cycle at 21 ± 1°C)
a n dp r o v i d e df o o da n dw a t e rad libitum. Animals were
excluded from the study if they developed post-surgery
infection, the osmotic pump or cannula was dislodged,
or placement of the cannula was not at specified coordi-
nates on post-mortem evaluation.
Surgical Procedures
A l ls u r g i c a lp r o c e d u r e s ,f o llowed previously described
methods [14,16]. Rats were anaesthetized with isofluorane.
Depth of anesthesia was monitored and adjusted as neces-
sary. All procedures were performed using sterile techni-
ques. Briefly, the head was incised using a sterile scalpel
blade; bleeding was minimized using cotton swabs. A hole
was drilled for placement of a skull screw to be used as
anchors for dental acrylic. A second hole was drilled over
the dorsal striatum for placement of a cannula at the
following coordinates: AP = +1.0 mm; ML = +3.0 mm and
V = -4.5 mm. 6-OHDA (20 μg/4 μL) was infused at a rate
of 0.5 μL per minute into the left striatum (PMID:
17346684). Immediately after the 6-OHDA lesion a stereo-
tactically implanted cannula (coordinates: AP = +1.0 mm;
ML = +3.0 mm and V = -4.5 mm) was affixed to the skull
by dental acrylic and attached to and osmotic minipump
inserted subcutaneously, for a sustained delivery of saline
for 7 days. After the first 7 days, a mid-scapular incision
was made and the saline pump was switched for the treat-
ment pump to deliver 3 ng/day (n = 5), 30 ng/day (n = 4),
or 90 ng/day (n = 5) of CX3CL1 or 90 ng/day of heat-inac-
tivated fractalkine (n = 6) (as a control) for 28 days into
the site of the lesion (Alzet model 2004: pumping rate 0.25
μl/hr (± 0.05 μl/hr); total volume 1.0 mL)a sp r e v i o u s l y
described [14]. After day 28 the rats were anesthetized and
perfused transcardially with phosphate buffered saline
(PBS) followed by 4% paraformaldehyde. Brains were then
removed and postfixed in paraformaldehyde overnight;
they were then transferred to a 30% sucrose/PBS solution
f o ra tl e a s t1 6h o u r s .C o r o n al sections were cut (40 μm)
using a cryostat and the sections were collected and stored
in a cryoprotectant solution at -20° until processing.
Immunohistochemistry
Tyrosine hydroxylase (TH) immunohistochemical stain-
ing was performed on free floating sections on every
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for the entire substantia nigra. With a random start, and
including sections before and after both anatomical
regions to make sure the entire structure was quantified.
Using standard staining procedure the sections were
pretreated with tris buffered saline/NaIO4 (sodium peri-
odate) for 20 minutes at RT (60 rpm) to block endogen-
ous peroxidase activity. Then washed with 0.1 M PBS
(pH 7.2-7.5). Tissue was then blocked with a PBS/0.3%
triton X-100/10% serum (Normal Horse serum; Lampire
Biological Labs; cat # 7333400) mixture for one hour at
room temperature. Sections were then incubated with
the primary antibody (mouse anti-TH, 1:10,000; Immu-
nostar cat# 22941) diluted into 3% horse serum with
0.3% Triton X-100 overnight at 4°C. The following day
the sections were washed and then incubated for one
hour with a biotinylated horse anti-mouse as secondary
antibody (Vector cat# BA-2001) at a concentration of
1:1000 in PBS-TS for an hour at room temperature. The
secondary antibody was amplified using avidin-biotin
substrate (ABC solution, Vector Cat# PK-6100) for
1 hour at room temperature. Finally the sections were
developed with 3,3’-Diaminobenzidine tetra-hydrochlor-
ide (SIGMA FAST ™ DAB). Sections were then
mounted onto glass slides and dried overnight. The next
day slides were pass trough a gradient of ethyl alcohol
and xylene to dehydrate the tissue. The slides were then
coverslipped using permount mounting medium
(Thermo Fisher Scientific Inc. Cat. # SP15-500).
OX-6, a marker for MHCII positive microglia, immuno-
histochemical staining was performed on free-floating sec-
tions following standard staining procedures with the
following adjustments: One in every third section was
stained including beginning to end of the striatum and
one in every six section was used beginning to end of the
substantia nigra. Sections were washed three times in PBS,
then tissue endogenous peroxidase activity was quenched
using 0.3% H2O2 solution combined with 40% methanol
for 20 min preceded by washing with PBS three times. Tis-
sue was then blocked with 10% normal horse serum and
0.3% Triton X-100. Monoclonal antibody was used as pri-
mary antibody directed against the rat major histocompat-
ibility II (mouse anti-RT1B; BD cat# 554926) at a
concentration of 1:750 into PBS-TS solution overnight at
4°C. On day 2 of this protocol, tissue was washed three
times with a solution of PBS enhanced with 3% horse
serum. Sections were then incubated with biotinylated sec-
ondary antibody (Horse anti-mouse with a concentration
of 1:300 from Vector cat # BA-2001) for an hour at room
temperature. The staining proceeded as described for TH
above with the exception that the DAB used contained
metal enhancer (Vector Cat# SK-4100).
NeuN immunohistochemistry was performed as pre-
viously mentioned following the standard staining
procedures to stain one in sixth free floating sections of
the substantia nigra. With the following alterations: To
quench endogenous peroxidase a solution of 40%
methanol/2% H2O2 was used. Additional washes pro-
ceded by a one hour incubation with blocking solution
of 10% horse serum and 0.3% Triton X-100. Primary
antibody incubation was performed using mouse anti-
NeuN (Millipore Cat# 3777) with a concentration of
1:1000 diluted into PBS-TS solution overnight at 4°C.
On the following day of this protocol tissue was washed
three times with PBS enhanced with 3% horse serum.
Sections were then incubated with a biotinylated sec-
ondary antibody horse anti-mouse (from Vector cat #
BA-2001) at a concentration of 1:300 for an hour at RT
in PBS-TS. The staining continued as indicated above
for TH staining.
Stereological Quantification
Stereological methods were used for quantification of
cells present in the tissue stained as previously described
[14,16]. Briefly, tissue was viewed with an Olympus
BX60 microscope and MicroBrightField, CX 9000 cam-
era. The tissue was quantified using optical fractionator
from MicroBrightField, software of Stereo Investigator
(Ver.8). The estimated volume (μm
3)o fT Hn e g a t i v e
zones was quantified using cavalieri method of unbiased
stereology in the striatum of every third section. Also,
the expression of OX-6 positive cells was quantified in
the striatum through the use of cavalieri. Both staining
were quantified using a grid spacing of 200 μmu s i n ga
2x/0.06 objective. TH positive cells are quantified within
t h ea r e ao ft h es u b s t a n t i an i g r ap a r sc o m p a c t a .T h e
sampling site is customized to count 200 cells per brain
sampling was with error coefficients less than 0.07. For
counting TH positive cells the counting frame (CF) is
70 × 70 with a virtual counting grid (CG) of 140 × 140.
For OX-6 cells CF is 400 × 300 and CG of 400 × 300.
For NeuN stain CF is 75 × 75 and CG is 160 × 160.
Statistical Analysis
Data are presented as mean cell number ± SEM aver-
aged across subjects per group, or mean volume ± SEM
averaged across subjects. Statistical comparison of the
data was performed using GraphPad Prism version 5.00
for Windows (GraphPad Software, San Diego California
USA, http://www.graphpad.com). Group interaction was
analyzed with one-way ANOVA, followed by Tukey
post-hoc analysis.
Results
CX3CL1 protects against 6-OHDA induces dopamine cell
loss and neurodegeneration
Intrastriatal 6-OHDA induces loss of dopamine term-
inals in the striatum and cell loss in the SNpc and is
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shows the loss of the TH immunoreactivity in the striatum
of rats 5 weeks after an injection of 6-OHDA. PD is a
slowly progressing neurodegenerative disease, which
requires substantial cell loss of the substantia nigra to
occur before clinical symptoms are evident. To determine
if the CX3CL1 signaling pathway could be protective dur-
ing the progressive degenera t i v ep h a s eo ft h ed i s e a s ew e
began a sustained intrastriatal infusion by osmotic mini-
pump of CX3CL1 beginning one week after the initial
insult of 6-OHDA and lasting for four weeks. Three doses
of CX3CL1 (3, 30, or 90 ng/day) were tested in this model
and compared to treatment with heat inactivated (HI)-
CX3CL1. As shown in Figure 1, all three doses of CX3CL1
resulted in a marked protection of the TH
+ terminals in
the striatum. Quantification of the amount TH
+ terminals
loss showed that all three concentration of CX3CL1
resulted in a similar 50% reduction in the size of the TH
negative zone (Figure 1.E). The amelioration of the lesion
size by CX3CL1 was significant for all three doses. There
was no difference between the different doses in the ability
to protect the terminal from degeneration.
CX3CL1 suppress the activation of microglia in the
striatum following a 6-OHDA insult
Signaling by CX3CL1 to the only known receptor,
CX3CR1, has been shown to be critical for restraining
microglia activation. Moreover, in the CNS, CX3CR1 is
only expressed on microglia [12,13,17]. The CX3CL1ef-
fects demonstrated by CX3CL1 in protecting the TH
+
terminals were hypothesized to occur by suppression of
microglia activation. The major histocompatibility com-
plex II (MHCII) is normally undetectable on microglia.
Activation of the microglia induces MHCII expression,
and presumably indicates a detrimental form of micro-
glia activation. To assess the activation of microglia we
stained for MHCII expression using the antibody OX-6.
A ss h o w ni nf i g u r e2 ,a t5w e e k sa f t e rt h e6 - O H D A
insult there was a large volume of OX-6 positive stain-
ing in the striatum of the HI-CX3CL1 treated rats. As
can be observed in figure 2B-C, there was a reduction in
MHCII staining in the CX3CL1 treated animals. Using
cavalieri method to assess the volume of MHCII expres-
sion we compared the effect of CX3CL1 in the STR in
all of the groups (Figure 2E). A significant decrease in
the volume of OX-6 positive cells was found in the rats
treated with 30 or 90 ng/day of CX3CL1.
Neuronal loss and microglia activation in the substantia
nigra is reduced by treatment with CX3CL1
To assess if this increased TH fiber density in the stria-
tum reflected a protection from cell death in the sub-
stantia nigra TH positive cells were counted in the
SNpc. Treatment with CX3CL1 at 3, 30, and 90 ng of
CX3CL1 resulted in significant protection from loss of
Figure 1 CX3CL1 reduces 6-OHDA induced lesion volume in
striatum: photomicrographs representing TH
immunohistochemistry following a 6-OHDA lesion. In the dorsal
striatum a noticeable decrease of TH immunoreactivity is seen in
the control group (HI CX3CL1; A) as compared to the groups who
received exogenous CX3CL1 for 28 days; 3 ng (B), 30 ng (C) CX3CL1
90 ng (D). Bar denotes 0.5 mm. Quantification of the TH negative
zone in the striatum of 3-month-old rats as determined by the
Cavalieri method of unbiased stereology, demonstrates significant
decrease in the TH negative immunoreactivity when CX3CL1 was
administered at the different concentrations (3, 30, and 90 ng) for
28 days (E). The group that received HI-CX3CL1 had a significant
larger lesion size. These findings indicate that CX3CL1 plays a
neuroprotective role in the 6-OHDA model of Parkinson disease.
One way ANOVA testing [F(3,19) = 7.149, p = 0.0029]. Asterisk
denotes significance (* P < 0.05) of Tukey post-hoc analysis compare
to HI-CX3CL1 group.
Figure 2 CX3CL1 suppresses microglia activation: Micrographs
of OX-6 positive cells (MHCII; a marker for actived microglia) show a
large increase in OX-6 staining in the control treated animals 5
weeks after a 6-OHDA in to striatum (A). Twenty-eight days infusion
of CX3CL1 3 ng (B), CX3CL1 30 ng (C), or CX3CL1 90 ng (D),
beginning 7 days after the insult with 6-OHDA show a clear
reduction in OX-6 staining. Bar denotes 0.5 mm. Arrow denotes
ameboid microglial cell (Panel A). Quantification of OX-6
immunoreactivity, by the Cavalieri method, found a significant
decrease in OX-6 expression when exogenous CX3CL1 was
administered (30 ng and 90 ng) as compared to the heat
inactivated control (E). One way ANOVA testing [F(3,19) = 4.172, p =
0.0232]. Asterisk denotes significance (* P < 0.05) of Tukey post-hoc
analysis compare to HI-CX3CL1 group.
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+ cells compared with HI-CX3CL1 (Figure 3E). To
confirm that the loss of TH
+ cells reflected cell death,
NeuN immunoreactive cells were also counted in the
SNpc (Figure 3F). The number of NeuN cells con-
firmed the results observed with TH
+ immunohisto-
chemistry that the administration of exogenous soluble
CX3CL1 helped protect the cell loss in the substantia
nigra. While CX3CL1 was delivered directly into the
striatum, protection of the terminals in the striatum
could result in decreased microglia activation in the
substantia nigra as a secondary interaction of less
dying neurons. Quantification of the number of OX-6
positive cells in the SNpc confirmed this hypothesis
(Figure 3G), and indicates that blocking inflammation
Figure 3 Neurodegeneration is prevented in the substantia nigra. Photomicrographs of TH immunoreactivity in substantia nigra
demonstrate a noticeable decrease in TH immunoreactivity in the control groups (A) as compared to the groups that received 3 ng (B), 30 ng
(C) and 90 ng of CX3CL1 (D). Bar denotes 0.2 mm. (E) Quantification of the number of TH
+ cells in the substantia nigra shows a significant
decrease of TH immunoreactivity in the substantia nigra of animals who receive HI CX3CL1 (control treatment) but this affect was reversed when
animals received 3, and 90 ng exogenous soluble CX3CL1 through and osmotic minipump for 28 days one week after a lesion with 6-OHDA.
One-way ANOVA, [F(3,19) = 9.498, p = 0.0008]. Asterisk denotes significance (* P < 0.05) compare to HI-CX3CL1 group; † denotes significance († P
< 0.05) compare to 90 ng CX3CL1 group as determined by Tukey post-hoc analysis. (F) Quantification of NeuN (neuronal nuclei marker)
immunohistochemistry in substantia nigra shows a significant decrease in the HI-CX3CL1 control group as compared to the groups of animals
treated with 3ng and 90 ng of CX3CL1. One-way ANOVA, [F(3,19) = 7.359, p = 0.0026]. Asterisk denotes significance (* P < 0.05) of Tukey post-hoc
analysis compare to HI-CX3CL1 group. (G) An increase in the number of OX-6
+ cells in substantia nigra was found in the HI-CX3CL1 control
group. CX3CL1This was significantly decreased by all three doses of CX3CL1. One-way ANOVA, [F(3,19) = 19.04, P < 0.0001]. Asterisk denotes
significance (* P < 0.05) compare to HI-CX3CL1 group by Tukey post-hoc analysis.
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in the substantia nigra.
Discussion
This study sought to determine if the CX3CL1/CX3CR1
axis would be amendable to therapeutic intervention in a
disease relevant animal model with a known inflammatory
component as part of the neurodegeneration. The results
of this study lend support to an important role of CX3CL1
in maintaining immune tolerance in the CNS. Following
treatment with CX3CL1 neuronal protection was found
that correlated with a reduction in microglia activation.
Since microglia are the predominant cells in the CNS that
express the CX3CL1 receptor, the effects of CX3CL1 are
most likely a direct effect on microglia activity [12,13,17].
The state of microglia was assessed by the expression of
MHCII, which is an often-used maker of a classical (M1)
proinflammatory state of activation. However, it should be
n o t e dt h a ti nt h i ss t u d yw ec a no n l yi n f e rf r o mt h e
changes in MHCII expression that CX3CL1 exerted the
effects by reducing inflammation, as no direct cytokine
measurements such as levels of IL-1b or iNOS were made.
CX3CL1/CX3CR1 is important for suppressing the pro-
duction of TNFa, IL-1b, IL-6 and INOS [11,12,18]; there-
fore, this effect of CX3CL1 to reduce cytokines and alter
microglial phenotype away from M1 is the most likely
interpretation of the data. There is a possibility that cannot
be excluded from the results of this study, that exogenous
CX3CL1 is having effects on cells other than microglia.
CX3CR1 is expressed on a subset of dendritic cells and
natural killer cells, peripheral blood monocytes and tissue
macrophages [19]. In vivo neurons do not appear to have
detectable levels of CX3CR1 [12,17], so while effects on
other subsets of immune cells can not be ruled out, it is
very unlikely that there is a direct effect of CX3CL1 of
neurons.
An unexpected finding of this study was the lack of a
dose response. A slight dose response was seen in some
of the measurements, but a significant difference
between the different treatment doses was not found. It
is possible that the range of doses of CX3CL1 chosen in
t h i ss t u d yw e r et o on a r r o wt od e m o n s t r a t ead o s e
response. A second possibility for the lack of the dose
response is that this signaling pathway, which is tonically
activated during normal physiological conditions, has
only a limited extra capacity to suppress glia activation.
Therefore at doses above 3ng/day of CX3CL1 there is an
excess of CX3CL1 to the amount of receptor available.
It has been previously shown that by 7 days after a MPP
+
lesion in rats there is an increase in CX3CR1 protein
levels in the substantia nigra; however, similar quantifica-
tion was not made of CX3CL1 [20]. It is therefore
unknown if a commensurate change in CX3CL1 is
also found. Our results would suggest there is an
increase CX3CR1 expression without a parallel increase
in CX3CL1, leading to an imbalance in the CX3CR1/
CX3CL1 axis. This imbalance is akin to what is seen in
the CX3CR1 KO mice where disruption in the CX3CR1/
CX3CL1 axis leads to neurotoxic inflammation [12].
A final possibility for the lack of a dose response
could be due to a floor affect. Such that, 50% of the
lesion occurs by 7 days before CX3CL1 treatment
began, and this primary neurodegeneration cannot be
reversed by CX3CL1 treatment; however, further neuro-
degeneration can be blocked by CX3CL1 treatment. We
have previously observed in this model that there is a
late phase of microglial activation that continues to
increase from 1 to 4 weeks following the lesion and that
if we block this late phase of inflammation we get neu-
roprotection; however, if we block the initial inflamma-
tion we can worsen neurodegeneration [16,21].
Nevertheless, all of the different concentrations of
CX3CL1 showed neuroprotection in this Parkinson dis-
ease relevant model. This suggests that the communica-
tion between neurons and glial cells may play a role in
Parkinson disease neurodegeneration.
Several reports have shown that CX3CL1 expression
decreases during aging, and this decrease correlates with
increased inflammation [14,15]. Consequently, changes
in CX3CL1 could be important for the dysregulation of
microglia in the age-related neurodegenerative disease.
Interruption of the CX3CL1/CX3CR1 axis by genetic
deletion causes neurodegeneration following stimulation
with lipopolysaccharide, MPTP, or SOD1 mutation [12].
Finally, a large single-bolus of CX3CL1 injected into the
substantia nigra has been shown to induce a Parkinson
disease like symptoms or even cause death. However, it
should be noted that the control for this injection of
CX3CL1 was normal saline. It is therefore, unknown if
the effects seen are due to the injection of a large
amount of recombinant protein, the bovine serum albu-
min that was used as a carrier for the CX3CL1, or if the
effect is indeed specific to CX3CL1 [20].
Conclusions
In conclusion, this study demonstrates that the
CX3CL1/CX3CR1 axis is an important target for drug
discovery to modulate microglia activation in PD.
Therefore, in the future it will be important to develop
selective small-molecule agonists for CX3CR1 that are
orally bioavailable and brain-penetrant. However, more
work is also necessary to determine the role of CX3CL1
and CX3CR1 in normal physiological conditions, as well
as, in models of neurodegenerative diseases.
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